India-based Zydus Lifesciences (including its subsidiaries and affiliates), has signed an exclusive development, licensi...
Pfizer’s NURTEC® (rimegepant), an orally disintegrating tablet for both the acute treatment of migraine is now...
Shanghai Junshi Biosciences Co. has collaborated with Indian pharmaceutical firm Dr. Reddy’s Laboratories to devel...
GSK Singapore announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5...
Japan headquatered Takeda's EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (N...
The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide sym...
A major clinical trial of an antibody treatment may soon pave the way for improved treatment of Alzheimer’s diseas...
German firm Heidelberg Pharma AG and Huadong Medicine in China have entered into a strategic partner...
Japanese firms Takeda Pharmaceutical Company and JCR Pharmaceuticals have announced a geographically-focused exclusive c...
South Korea-based Samsung Bioepis has announced that the US Food and Drug Administration (FDA) has approved BYOOVIZ...
US-based Mirum Pharmaceuticals, Inc. and Japanese firm Takeda Pharmaceutical have entered into an exclusive licensing ag...
Australian patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new...
Eli Lilly Japan and Daiichi Sankyo Company have concluded an agreement on commercialisation collaboration in Japan for t...
Japan-based Eisai and FUJI YAKUHIN have inked a license agreement concerning dotinurad (generic name), a treatment for h...
Singapore-based Menarini Asia-Pacific Holdings, a part of the leading Italian global biopharmaceutical company Menarini ...
The UK National Institute for Health and Care Excellence (NICE) has published new draft guidance which recommends Eli Li...
U.S. Food and Drug Administration (FDA) has approved a combination therapy from Eisai and Merck (MSD) namely,&...
Yuyu Pharma and Novartis Korea have entered into an agreement in which Yuyu will have exclusive distribution rights for ...
